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Abstract Rat C6 glioma cells have been used to characterize 
molecular events involved in the regulation of inducible nitric 
oxide synthase (iNOS) gene expression stimulated by interferon-
γ(ΙΡΝ-γ) plus lipopolysaccharide (LPS). IFNs induce a signaling 
event which involves activation of Statl transcription factor. 
Previous studies have shown that IFNs also induce extracellular 
signal-regulated kinase/mitogen-activated protein kinase (ERK/ 
MAPK) activation. However, the mechanisms by which IFNs 
stimulate MAPK activation remain elusive. Here we show that in 
C6 glioma cells, transiently expressing the dominant-negative 
form of c-Ha-Ras (Asn-17) abrogated IFN-y-induced ERK1 and 
ERK2 activation. Furthermore, PD98059, a specific MEK1 
inhibitor, also blocked this activation. These results indicate that 
p21ras and MEK1 are required for IFN-Y-induced ERK1 and 
ERK2 activation. Recent studies have reported that MAPK is 
responsible for serine phosphorylation of Statl which is required 
for Statl's DNA binding and maximal transcriptional activity. 
Thus, we examined the role of the Ras-MAPK pathway in Statl 
activation and subsequent iNOS induction in C6 glioma cells. 
Further experiments showed that neither Asn-17 Ras expression 
nor concentrations of PD98059, which completely abrogated 
IFN-Y-induced ERK1 and ERK2 activation, affected Statl DNA 
binding activity or iNOS induction, indicating that the Ras-
MAPK pathway does not appear to be involved in the activation 
of Statl and subsequent iNOS induction in C6 glioma cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
There are three gene products which are known to act as 
nitric oxide synthase (NOS). The high-output inducible NOS 
isoform (iNOS) is expressed in different cell lines, tissues and 
species in response to various cytokines (such as IFN-γ, IL-lß 
and TNF-a) and microbial products (including lipopolysac-
charide (LPS)) [1]. iNOS plays critical roles in many biological 
processes, such as host defense, vasodilation, synaptic plastic-
ity and neurotransmission [2]. In contrast, iNOS contributes 
to the pathogenesis of various diseases and leads to organ 
destruction in some inflammatory [3] and autoimmune dis-
eases [4]. Therefore, to regulate production and prevent ad-
verse effects of iNOS-produced nitric oxide (NO), it is neces-
sary to understand how expression of iNOS is regulated. 
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Unfortunately, the signaling events involved in iNOS ex-
pression are not well understood. It has been suggested that 
two positions on the murine macrophage iNOS gene promoter 
region that contain a KB site and IFN-y-activated site (GAS) 
are necessary for iNOS induction in response to IFN-y/LPS 
[5,6]. In glial cells, iNOS induction stimulated by IFN-y/LPS 
has been reported to require tyrosine kinase activity [specifi-
cally, JAK2] [7-9]. IFN-γ activates the Janus kinases JAK1 
and JAK2 and subsequent tyrosine phosphorylation, nuclear 
translocation and binding of Statl transcription factor to the 
GAS element [10]. Statl is also phosphorylated on serine as 
well as tyrosine residue [11]. The substitution of Ser-727 with 
Ala-727 renders Statl unable to induce transcription [11]. The 
COOH-terminal region of Statl (-Pro-Met-727Ser-Pro-) is sim-
ilar to the MAPK recognition consensus sites [11,12]. David 
and colleagues [12] have noted that ERK2 constitutively asso-
ciates with the IFNot/ß receptor and enzymatically activated 
and associated with Statl in response to IFN-ß. IFN-γ has 
also been shown to induce the activation of MAPK in several 
cell types [13,14], although the pathway(s) involved in this 
event are unclear. 
We studied the mechanisms of MAPK activation in re-
sponse to IFN-γ. Furthermore, we investigated whether or 
not the Ras-MAPK pathway is involved in IFN-Y-induced 
DNA binding of Statl and IFN-Y/LPS-enhanced iNOS induc-
tion in C6 glioma cells. Here we showed that either expression 
of dominant-negative mutant of c-Ha-Ras (Asn-17) in C6 cells 
or pretreatment of the C6 cells with PD98059, a specific 
MEK1 inhibitor, led to a repression of IFN-Y-induced 
ERK1 and ERK2 activation. This suggests that p21 r a s and 
MEK1 are required for IFN-Y-induced ERK1 and ERK2 ac-
tivation. However, neither Asn-17 Ras expression nor 
PD98059 affected IFN-Y-induced DNA binding of Statl to 
the GAS element, or on IFN-Y/LPS-induced iNOS induction. 
Thus, the Ras signaling pathway may not be involved in the 
activation of Statl and subsequent iNOS induction in C6 
cells. 
2. Materials and methods 
2.1. Cell culture and DNA transfection 
Rat C6 glioma cells (American Type Culture Collection) were main-
tained in F-10 medium (Gibco) supplemented with 15% horse serum 
(Gibco), 2.5% fetal calf serum (Boehringer Mannheim), 50 μg/ml pen-
icillin and 100 μg/ml streptomycin in a humidified incubator contain-
ing 5% C02. 
C6 cells were transfected by lipofectAMINE reagent (Gibco) with 
the vector P3'C:\TMP\equSS (Stratagene) expressing the LACI re-
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pressor and inhibitory Asn-17 Ras [15] cloned into the LACI repres-
sible pOPRSVl vector (Stratagene). Stable clones were selected in 400 
μg/ml hygromycin B (Wako) and 400 μg/ml G418 (Gibco) and 
screened for inducible expression of c-Ha-Ras by immunoblotting. 
Incubation in 5 mM isopropyl-1-thio-ß-D-galactopyranoside (IPTG) 
(Wako) for 8-24 h was used to induce Ras expression. Several inde-
pendent, inducible Asn-17 Ras clones were isolated, and the most 
expressive one was chosen for further analysis. 
2.2. MAP kinase assays 
C6 cells (6.2 X 106) were washed with 10 ml of ice-cold PBS, scraped 
into 1 ml of lysis buffer (9.1 mM Na2HP04 , 1.7 mM NaH2P04 , 150 
mM NaCl, 1 mM Na3V04 , 10 mM NaF, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 μg/ml aprotinin, and 10 μg/ml leupeptin, pH 7.4) and 
broken by passage through a 21-gauge needle. The lysates were on 
ice for 1 h and centrifuged at 15000 rpm for 20 min at 4°C. The 
supernatants were subjected to ERK1 or ERK2 immunoaffmity col-
umn (Santa Cruz). The partially purified ERK1 or ERK2 was boiled 
with SDS sample buffer for 3 min and resolved in 10% SDS gel in 
which myelin basic protein (MBP) (Sigma) were precrosslinked. Gels 
were washed in 50 mM 2-[4-(2-hydroxyethyl)-l-piperazinyl]-ethanesul-
fonic acid (Hepes), pH 7.4, containing 20% 2-propanol for 1 h (100 ml 
each, two changes) at room temperature (r.t.) to remove SDS. Gels 
were then washed in 250 ml of buffer A (50 mM Hepes, pH 7.4, 5 mM 
2-mercaptoethanol) for 1 h at r.t.. Next, gels were treated in buffer A 
containing 6 M guanidine-HCl for 1 h at r.t., then renatured in buffer 
A containing 0.04% Triton X-100 for 16 h at 4°C (250 ml each, four 
changes). Gels were incubated in buffer B (25 mM Hepes, pH 7.4, 10 
mM MgCl2 and 2 mM dithiothreitol (DTT)) for 1 h at 25°C. The 
kinase reaction was performed in buffer C (25 mM Hepes, pH 7.4, 10 
mM MgCl2, 0.5 mM EGTA, 2 μΜ cAMP-dependent protein kinase 
inhibitor (Sigma), 40 mM nonradioactive ATP and 10 μθ/piιΐ [γ-
32P]ATP (Dupont NEN)) for 1 h at 25°C. Gels were extensively 
washed with a solution of 5% TCA and 10 mM sodium pyrophos-
phate for 2 h at r.t. (250 ml each, four changes), dried on Whatman 
3MM paper and subjected to autoradiography. Band quantitation 
was performed using FUJIX BASTATION software (Fuji Photo 
Film Co.). MAPK electrophoretic shift and its presence were deter-
mined by immunoblotting using anti-ERKl polyclonal antibody 
(pAb) (Santa Cruz) or anti-ERK2 monoclonal antibody (mAb) 
(UBI). In this case, polyacrylamide gels with an acrylamide/bisacryl-
amide ratio of 30:0.2 were used (30:0.8 acrylamide/bisacrylamide gels 
were used for other experiments). Tyrosine phosphorylation of 
MAPK was determined by immunoblotting using anti-phosphotyro-
sine (pY) mAb (4G10) (UBI). 
2.3. Phosphoamino acid analysis 
The analyses were performed essentially as described by Boyle et al. 
[16]. Cells were starved for 2 h in phosphate-free DMEM (Sigma) 
with 15% horse serum and 2.5% fatal calf serum dialyzed against 
physiological saline. The labeling was carried out with 0.4 mCi/ml 
of [32P] orthophosphate (Dupont NEN) for 4 h in medium otherwise 
lacking in phosphate. ERK1 proteins were partially purified as men-
tioned above and subjected to 11% SDS-PAGE and autoradiography. 
The 32P-labeled ERK1 proteins were recovered after SDS-PAGE, di-
gested with tosylphenylalanyl chloromethylketone (TPCK) -treated 
trypsin (0.33 mg/ml; Worthington Biochemical Corporation) in 50 
mM NH4HCO3 and lyophilized. Phosphopeptides were hydrolyzed 
in 6 N HC1 for 90 min at 110°C. Phosphoamino acids were spotted 
onto TLC plates (Merck, Art 5716), and separated by electrophoresis 
at pH 3.5. TLC plates were dried, exposed to imaging plates and 
visualized on a Fuji BAS 2000 (Fuji Photo Film Co.). Positions of 
individual phosphoamino acids were determined by comparison with 
the comigration of commercially available standards (Sigma) after 
staining with ninhydrin. 
2.4. Electrophoretic mobility shift assays (EMSA) and antibody 
inhibition 
Nuclear extracts were prepared using a slight modification of the 
method described by Schreiber et al. [17]. Briefly, 3.1 XlO6 cells were 
harvested, washed once with 2 ml of ice-cold PBS and resuspended in 
400 μΐ of buffer A (10 mM Hepes, pH 7.9, 10 mM KC1, 0.1 mM 
EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 10 μg/ml apro-
tinin, and 10 μg/ml leupeptin). After incubation on ice for 15 min, 
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Nonidet P-40 was added to a final concentration of 0.6%, and vigo-
rously vortex-mixed for 10 s. The lysates were then centrifuged at 
15 000 rpm for 30 s at 4°C. The supernatants were removed and 
subjected to immunoblotting using anti-Ras mAb. The pellets (crude 
nuclei) were resuspended in 50 μΐ of buffer B (20 mM Hepes, pH 7.9, 
0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 
10 μg/ml aprotinin, and 10 μg/ml leupeptin) and were vigorously 
vortex-mixed for 15 min at 4°C. The lysates were centrifuged at 
15000 rpm for 5 min at 4°C and the supernatants containing the 
nuclear proteins were transferred into fresh vials. The protein concen-
trations of extracts were measured using a Bio-Rad protein assay kit. 
EMSA was performed by incubating 5 μg of nuclear extracts with 
2 μg of poly(dl-dC) (Pharmacia Biotech) in binding buffer (13 mM 
Hepes, pH 7.9, 65 mM NaCl, 0.15 mM EDTA, 1 mM DTT, 0.02% 
Nonidet P-40, 1 mg/ml bovine serum albumin (BSA), and 5% glycer-
ol) (20 μΐ final volume) for 15 min on ice. Then, an end-labeled, 
double-stranded oligonucleotide probe (50000 cpm/0.3 ng) was added 
and the reaction mixture was incubated for 15 min at 25°C. The probe 
(5'-GTATTTCCCAGAAAAGG-3') contained a core sequence corre-
sponding to the IFN-γ response region (GRR) of the Fey receptor 
typegene [18]. Protein-DNA complexes were separated by electropho-
resis in 0.25 XTBE (Tris-Borate-EDTA) buffer through a 3.5% poly-
acrylamide gel. Gels were dried, exposed to imaging plates and visual-
ized on a FUJI BAS2000. For supershift assay with specific antibody 
against the Statl C-terminal region (Santa Cruz), nuclear extracts 
were preincubated with 1 μg of antibody or 1 μg of normal rabbit 
serum for 1 h at 4°C before the probe was added. 
2.5. Preparation of crude cytosol and membrane fractions 
Cells (1.1 X 106) were washed with 4 ml of ice-cold PBS, added 200 
μΐ of ice-cold buffer A (PBS, pH 7.4, 1 mM PMSF, 10 μg/ml aprotinin 
and 10 μg/ml leupeptin), harvested and sonicated for 5 s. The lysates 
were centrifuged at 15000 rpm for 20 min at 4°C, and the super-
natants were removed and used as crude cytosol fractions. The pellets 
were resuspended in 100 μΐ of ice-cold buffer A, sonicated for 5 s and 
used as crude membrane fractions. Crude cytosol and membrane 
fractions were boiled with SDS sample buffer for 5 min and subjected 
to immunoblotting using anti-maciNOS mAb and anti-Ras mAb, re-
spectively. Protein concentrations of each fraction were measured us-
ing a Bio-Rad protein assay kit. 
2.6. Immunoblotting 
All immunoblots were blocked in TBST (50 mM Tris-HCl, pH 7.4, 
100 mM NaCl, 0.1% Tween 20) containing 1% BSA and then incu-
bated with a 1:200 dilution (anti-ERKl pAb) (Santa Cruz), 1:250 
dilution (anti-ERK2 mAb) (UBI), 1:500 dilution (anti-Ras mAb) 
(Transduction laboratories), 1:1000 dilution (anti-pY mAb) (UBI), 
or a 1:2500 dilution (anti-macNOS mAb) (Transduction laboratories) 
in TBST. The blots were washed and incubated with a 1:2000 dilution 
of anti-mouse or -rabbit Ig-horseradish peroxidase conjugate (Amer-
sham) in TBST. After several washes, antibody-reactive bands were 
visualized by enhanced chemiluminescence (ECL Western detection 
kit; Amersham). 
2.7. RNA isolation and Northern blot analysis 
Total cellular RNA was isolated from 1.2 X107 cells by acidic gua-
nidinium thiocyanate-phenol-chloroform extraction [19]. A 30 μg 
amount of total RNA was denatured by heating 65°C for 15 min in 
2.2 M formaldehyde, 50% (v/v) formamide, electrophoresed in 1% 
agarose gels containing 2.2 M formaldehyde and then transferred 
on nitrocellulose filters by capillary action using 20XSSC ( lxSSC 
is 0.015 M sodium citrate buffer, pH 7.0, containing 0.15 M NaCl). 
Filters were prehybridized for 7 h at 42°C in a solution containing 
50% formamide, 50 mM NaH2P04 , 5XSSC, 1 XDenhardt's solution 
and 40 μ^piύ salmon sperm DNA, and then incubated for 16 h at 
42°C with 32P-labeled, randomly-primed cDNA fragments. After 
washing the filters twice at r.t. in 2XSSC, 0.1% SDS for 15 min 
and twice at 68°C in 1 XSSC, 0.1% SDS for 15 min, autoradiography 
was performed by exposing the filter to imaging plates and visualizing 
then on a FUJI BAS2000. Between hybridizations using different 
cDNA probes, probes were stripped off of the membrane by boiling 
for 20 min in distilled water. The DNA probes used were a 700-bp 
fragment from the 5' end of the rat liver iNOS cDNA [20], a 700-bp 
Hindlll-Pstl fragment of the human p21 ras cDNA, and a 600-bp PCR 
fragment from the rat ß-actin cDNA. 
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Fig. 1. ERKl and ERK2 were phosphorylated and activated in response to IFN-γ in C6 cells. (A) MAPK electrophoretic shift by IFN-γ. C6 
cells were treated for indicated times with 250 U/ml IFN-γ (Gibco). ERKl and ERK2 were isolated from cell lysates by ERKl or ERK2 im-
munoaffinity column. Partially purified ERKl or ERK2 was fractionated by SDS-PAGE (acrylamide/bisacrylamide, 30:0.2), transferred to ni-
trocellulose, and immunoblotted using anti-ERKl pAb or anti-ERK2 mAb. (B) Tyrosine phosphorylation of ERKl and ERK2 by IFN-γ. Par-
tially purified ERKl or ERK2 was fractionated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted using anti-pY mAb. 
Phosphoamino acid analysis of partially purified ERKl isolated from 32P-labeled C6 cells untreated or treated with 250 U/ml IFN-γ for 15 min 
was performed as described in Section 2. (C) ERKl and ERK2 activation by IFN-γ. ERKl and ERK2 activity were analyzed by in gel MBP 
kinase assay as described in Section 2. 
3. Result 
3.1. IFN-yinduces phosphorylation and activation of ERKl and 
ERK2 in C6 cells 
First, we examined whether or not IFN-γ induces MAPK 
activation in C6 cells. Three techniques previously established 
for assaying MAPK activation were simultaneously used: (1) 
electrophoretic shift of MAPK, (2) tyrosine phosphorylation 
of MAPK, and (3) in gel kinase assay using MBP as a sub-
strate (see Section 2). Fig. 1A shows the electrophoretic shift 
of MAPK stained with anti-ERKl or ERK2 antibody in 
which the slower migrating form represents phosphorylated 
MAPK. The slower migrating ERKl was detected in a quies-
cent state, while the slower migrating ERK2 was detected in a 
time-dependent fashion. However, as shown in Fig. IB, the 
immunoblot with anti-phosphotyrosine antibody showed that 
IFN-γ induced tyrosine phosphorylation of both ERKl and 
ERK2 in a time-dependent fashion as can be seen in the figure 
as the ERK2 electrophoretic shift. Phosphoamino acid anal-
ysis of partially purified ERKl from 32P-labeled C6 cells dem-
onstrated that basal phosphorylation occurred on serine. 
Treatment of the C6 cells with IFN-γ for 15 min resulted in 
the additional appearance of both phosphothreonine and 
phosphotyrosine, suggesting that the appearance of the slower 
migrating ERKl in a quiescent state is due to phosphoryla-
tion of serine residues at the basal level. To directly determine 
whether MAPK activity was enhanced as a result of IFN-γ 
treatment of cells, we assayed MAPK activity using MBP as a 
substrate. As shown in Fig. 1C, IFN-γ stimulation increased 
phosphorylation of MBP by ERKl and ERK2 within 5 min, 
and became maximal at 15 min, decreasing thereafter. 
3.2. Expression of Asn-17 Ras inhibits IFN-y-induced ERKl 
and ERK2 activation in C6 cells 
It has been shown that a large number of growth factors 
activate MAPK via p21 ras. To study whether or not the Ras 
Fig. 2. Expression of dominant-negative Asn-17 Ras blocks IFN-y-induced ERKl and ERK2 activation in C6 glioma cells. (A) Inhibition of 
ERKl activation by IFN-γ in Asn-17 Ras-expressing C6 cells. Lad (lanes 1^ 1) or Asn-17 Ras cells (lanes 5-8) were uninduced (—) or induced 
(+) with 5 mM IPTG for 24 h. Cells were unstimulated (—) or stimulated (+) for 15 min with 250 U/ml IFN-γ. ERKl activity was assayed as 
in Fig. 1. (B) Inhibition of ERK2 activation by IFN-γ in Asn-17 Ras-expressing C6 cells. Lad or Asn-17 Ras cells were induced with IPTG, 
stimulated as indicated, and analyzed for ERK2 activation. (C) Immunoblot of Asn-17 Ras expression. Of each cell lysates, 20 μg were frac-
tionated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted using anti-Ras mAb. 
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Fig. 3. PD98059 blocks IFN-y-induced ERK1 and ERK2 activation 
in C6 glioma cells. C6 cells were pretreated for 1 h with PD98059 
(New England Biolabs) at the indicated concentrations followed by 
incubation with (+) or without (—) 250 U/ml IFN-γ for 15 min. 
ERK1 and ERK2 were isolated from cell lysates and their activities 
were assayed as in Fig. 1. 
signaling pathway is involved in IFN-y-induced MAPK acti-
vation, the Lac Switch-inducible expression system (see Sec-
tion 2) was used to control the expression of the dominant-
negative mutant of c-Ha-Ras (Asn-17) in C6 cells. Fig. 2 
shows the functional consequence of expressing Asn-17 Ras 
on MAPK activation in response to IFN-γ. IPTG-regulated 
expression of Asn-17 Ras is shown in Fig. 2C. Expression of 
Asn-17 Ras inhibited IFN-y-induced activation of ERK1 (Fig. 
2A) and ERK2 (Fig. 2B) (decreased 65% and 85%, respec-
tively). Electrophoretic shift and tyrosine phosphorylation of 
MAPK in response to IFN-γ were also inhibited by expression 
of Asn-17 Ras (data not shown), suggesting that IFN-γ-ίη-
duced MAPK activation is mediated by p21 r a s . Expression 
of Asn-17 Ras, however, could not completely block the 
IFN-y-induced MAPK activation. It is likely that the level 
of Asn-17 Ras expression was too low to completely block 
endogenous Ras or that IFN-γ activates MAPK via a Ras-
independent pathway. It was surprising that, as shown in Fig. 
2, phosphorylation of MBP by ERK1 was also detected. This 
suggests that different lots of ERK2 immunoaffinity column 
were used between the experiments shown in Figs. 1 and 2. 
The ERK2 immunoaffinity column used in Fig. 2 had cross-
reacted with ERK1 proteins. Indeed, when purified proteins 
isolated by the ERK2 immunoaffinity column used in Fig. 2 
were subjected to immunoblotting using anti-ERKl pAb, 
ERK1 proteins were detected in addition to ERK2 proteins 
(data not shown). 
3.3. PD98059, a specific MEK1 inhibitor, blocks IFN-y-induced 
ERK1 and ERK2 in C6 cells 
It is generally known that MAPK activation in response to 
growth factors, such as EGF, NGF, or PDGF, requires phos-
phorylation at both threonine and tyrosine residues by a dual 
specificity kinase, MEK. Because PD98059 was recently de-
scribed by Dudley et al. [21] as a synthetic inhibitor of MEK1, 
specifically activating ERK1 and ERK2, we analyzed whether 
the addition of PD98059 blocks IFN-y-induced ERK1 and 
ERK2 activation. As shown in Fig. 3, PD98059 blocked 
ERK1 and ERK2 activity toward MBP in a concentration-
Fig. 4. Effects of herbimycin A, PD98059 and Asn-17 Ras expression on DNA binding of Statl in response to IFN-γ in C6 glioma cells. C6 
cells were pretreated for 12 h with herbimycin A (lanes 5-8) or for 1 h with PD98059 (lanes 9-12) at the indicated concentrations followed by 
incubation with 250 U/ml IFN-γ for 30 min before preparing nuclear extracts for analysis by EMS A. Lad (lanes 13-16) or Asn-17 Ras cells 
(lanes 17-20) were pretreated for 24 h with 5 mM IPTG followed by incubation with 250 U/ml IFN-γ for 30 min. Then, nuclear extracts and 
whole cell lysates were prepared and subjected to EMSA and immunoblotting using anti-Ras mAb, respectively. 
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Fig. 5. Asn-17 Ras expression in C6 cells does not alter iNOS in-
duction stimulated by IFN-y/LPS in C6 glioma cells. (A) Crude cy-
tosol and membrane fractions were prepared from Lad (lanes l^f) 
or Asn-17 Ras cells (lanes 5-8) pretreated for 24 h with 5 mM 
IPTG followed by stimulation with 250 U/ml IFN-γ/ΙΟ μg/ml LPS 
(from Escherichia coli Serotype 055:B5, Sigma, L-2637) for 24 h. 
Crude cytosol fractions (30 μg) were subjected to immunoblotting 
using anti-maciNOS mAb, and crude membrane fractions (10 μg) 
were subjected to immunoblotting using anti-Ras mAb. (B) Total 
RNAs were isolated from Lad (lanes 1^ 1) or Asn-17 Ras cells 
(lanes 5-8) pretreated for 24 h with 5 mM IPTG followed by stimu-
lation with 250 U/ml IFN-γ/ΙΟ μg/ml LPS for 24 h and subjected to 
Northern blot analysis using 32P-labeled cDNA derived from rat 
iNOS and human Ras as described in Section 2. 32P-labeled cDNA 
derived from rat ß-actin was used as a control for the amounts of 
RNA used in each lane. Exposure times, 12 to 48 h. 
dependent fashion. It appears, therefore, that IFN-y-induced 
ERK1 and ERK2 activation is mediated by the classical 
MAPK cascade. 
3.4. IFN-y-induced DNA binding of Stall and 
IFN-ylLPS-stimulated iNOS induction are independent 
of the Ras-MAPK pathway in C6 cells 
According to functional analysis using deletion mutants of 
a 1753-bp fragment of the promoter region of iNOS cloned 
from the murine RAW 264.7 macrophage cell line, positions 
50 to 250 and 900 to 1030 are important regulatory regions 
for iNOS induction stimulated by IFN-y/LPS, each containing 
a KB site for NF-κΒ and an IFN-y-activated site (GAS) for 
Statl homodimer [5,6]. We have previously demonstrated that 
IFN-y-induced JAK2 activation can be involved in iNOS in-
duction stimulated by IFN-y/LPS in C6 cells [8]. JAK2 indu-
ces tyrosine phosphorylation and nuclear translocation of 
Statl transcription factor [10]. It has recently been suggested 
that H7, a serine/threonine kinase inhibitor, blocks IL-6-in-
duced nuclear translocation and DNA binding of Stat3 [22]. 
Furthermore, the mutants of Ser-727 in Statl and Stat3 
greatly reduced the ability of Statl and Stat3 to induce tran-
scription. These mutants are present in the highly-conserved 
sequence (-Pro-Met-Ser-Pro-) in the COOH-terminal region of 
Statl, Stat3, and Stat4 and in the sequence (-Pro-Leu-Ser-Pro-) 
in Stat5, which are similar to MAPK recognition consensus 
sites [23,24]. Therefore, we determined whether Asn-17 Ras 
expression or PD98059 inhibits DNA binding of Statl in re-
sponse to IFN-γ by EMSA using 32P-labeled GRR GAS. Ac-
cording to the supershift analysis by specific antibody against 
the Statl C-terminal region, it was confirmed that Statl is the 
protein which translocates to the nucleus and binds to GRR 
GAS in response to IFN-γ (Fig. 4, lanes 1-4). Herbimycin A, 
a specific tyrosine kinase inhibitor [25] which potently inhibits 
iNOS induction stimulated by IFN-y/LPS in C6 cells [8], abol-
ished IFN-y-induced DNA binding of Statl to GRR GAS in 
a dose-dependent fashion (Fig. 4, lanes 5-8). However, addi-
tion of up to 50 μΜ PD98059 to cells had no effect on Statl 
DNA binding activity (Fig. 4, lanes 9-12). Similarly, no effect 
was observed on this event with expression of Asn-17 Ras 
(Fig. 4, lanes 19 and 20). 
Wen et al. [11] have suggested that phosphorylation of Ser-
727 in Statl and Stat3 has no effect on their DNA binding 
activity, but greatly reduces their ability to induce transcrip-
tion. We then determined the effect of Asn-17 Ras expression 
on iNOS induction stimulated by IFN-y/LPS in C6 cells by 
immunoblot and Northern blot analysis. We found that ex-
pression of Asn-17 Ras has no effect on this iNOS induction 
at either the transcription (Fig. 5B, lanes 7 and 8) or trans-
lation stage (Fig. 5A, lanes 7 and 8). PD98059 also appears to 
have no effect on the accumulation of NO2, a breakdown 
product of NO produced by the iNOS induction (data not 
shown). We have therefore concluded that the Ras-MAPK 
pathway does not contribute to the activation of Statl and 
subsequent iNOS induction in C6 cells. 
4. Discussion 
The present data show that in C6 glioma cells, both expres-
sion of dominant-negative Asn-17 Ras and PD98059 attenu-
ates IFN-y-induced ERK1 and ERK2 activation (Figs. 2 and 
3). These findings indicate that IFN-y-induced ERK1 and 
ERK2 activation appears to be mediated by the classical 
MAPK cascade via p21 ras in C6 cells. However, the IFN-y 
signaling events in C6 cells upstream of the Ras-MAPK path-
way remain unclear. Winston and Hunter [26] have recently 
reported that in human embryonic kidney 293 cells, growth 
hormone (GH)-stimulated ERK2 activation requires transient 
expression of JAK2 and that this activation is inhibited both 
by dominant-negative Ras and dominant-negative Raf-1. In 
addition, in 3T3L1 cells JAK2 has been reported to co-immu-
noprecipitate with Grb2 or Fyn by IL-11 [27]. Both GH [28-
30] and IL-11 [31] activate JAKs and STATs as well as the 
MAPK cascade. The present findings show that MAPK ac-
tivity is maximal at 15 min after IFN-y stimulation, which is 
markedly slower than growth factors. Surprisingly, the time 
course of this activation coincided with that of tyrosine phos-
phorylation of Statl in C6 cells (data not shown). Therefore, 
it is reasonable to presume that JAK2 is a common compo-
nent in the JAK-STAT and Ras-MAPK pathways activated 
38 T. Nishiya et al.lFEBS Letters 408 (1997) 33-38 
by various growth factors or cytokines, both of which activate 
two different pathways. It seems that the signal caused by 
these stimuli branches off from JAK2 into these two signaling 
pathways. 
Recently, the signal interaction between the JAK-STAT 
and R a s - M A P K pathways has attracted considerable atten-
tion. It is well known that tyrosine phosphorylation is neces-
sary for dimerization, nuclear translocation and D N A binding 
of STATs [10]. Recently, it has been reported that serine 
phosphorylation of Stat l and Stat3 is required for D N A bind-
ing activity [22] and maximal transcriptional activity [11]. It 
has been suggested that the activation of STATs might be 
regulated by M A P K for a number of reasons. The serine 
phosphorylation site in Stat l is present in a consensus se-
quence recognized by M A P K , and Stat l is a substrate for 
M A P K in vitro [11]. In addition, Stat l co-immunoprecipitates 
with E R K 2 in IFN-ß-treated cells, and M A P K activity is 
required for Stat-dependent transactivation induced by I F N -
ß [12]. However, in HC11 mammary epithelial cells, concen-
trations of PD98059 which completely abrogated lactogenic 
hormone-induced M A P K activation did not affect either the 
phosphorylation state of Stat5, its D N A binding activity or 
transcriptional activation of the ß-casein gene promoter [32]. 
In Kit 225 human T cells, H7 did not prevent E R K 2 activa-
tion, but did suppress the phosphorylation of Stat5 [33]. Fi-
nally, in human hepatoma HepG2 cells, the transcriptional 
activity of Stat3 induced by IL-6 was not inhibited by a dom-
inant-negative Ras protein [34]. Here we showed that inhib-
ition of IFN-y-induced M A P K activation with dominant- neg-
ative Ras or PD98059 does not affect the D N A binding of 
Stat l by IFN-γ (Fig. 4). These findings suggest that M A P K 
activity does not appear to be involved in Stat l activation by 
IFN-γ. 
It is clear that the G A S element is present in the promoter 
region of the murine macrophage iNOS gene and is important 
in promoter activity [5,6]. It has been suggested that tyrosine 
kinase activity is required for iNOS induction stimulated by 
IFN-y/LPS in glial cells [7-9]. We have previously demon-
strated that JAK2 is involved in iNOS induction stimulated 
by IFN-y/LPS in C6 cells [8]. In addition, we report here that 
D N A binding of Stat l is affected in herbimycin A-treated C6 
cells (Fig. 4), which inhibits iNOS induction stimulated by 
IFN-y/LPS [8]. However, neither dominant-negative Ras nor 
PD98059 has any effect on iNOS induction stimulated by 
IFN-y/LPS in C6 cells (Fig. 5). Therefore, these findings in-
dicate that IFN-y-induced Stat l activation, but not M A P K 
activation, is important for iNOS induction stimulated by 
IFN-y/LPS. This supports the hypothesis that M A P K is not 
responsible for S ta t l ' s ability to induce transcription. 
In summary, our data demonstrate that IFN-γ activates the 
dual intracellular signaling pathways of JAK-STAT and Ras-
M A P K , suggesting that these two pathways do not appear to 
converge with M A P K modification of S ta t l . It is possible that 
IFN-γ plays essential roles in various biological systems by 
activating two different signaling pathways at the same time 
in C6 cells. Fur ther investigations are required to identify the 
upstream of Ras which is involved in IFN-y-induced M A P K 
activation and to understand the physiological functions of 
IFN-γ induced activation of M A P K in C6 cells. 
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